1. Lawsuit-ridden J&J tumbles in annual listing of best global brands — AstraZeneca gets Q2 2020 PDUFA date for breast cancer ADC — Shionogi's antibiotic clears FDA panel vote — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

US Division

Discussion in 'Basilea' started by Anonymous, Aug 10, 2007 at 10:02 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    When are they starting their US division?
     
  2. Anonymous

    Anonymous Guest

    From what I have heard the folks at Ortho Mcneil (J&J) will be promoting their anti-infectives...
     
  3. Anonymous

    Anonymous Guest

    OMP hospital reps. will be co-promoting the product (re-read the press release or go to JNJ'w web site).
     
  4. Anonymous

    Anonymous Guest

    Supposed to start a division within US.... Anyone hear of a US recruiter handling sales force? Delayed ceftobiprole US launch until March/April...
     
  5. Anonymous

    Anonymous Guest

    Where did you get that crap (out your ass maybe)?
    The PFUDA date is in November.
    They have not hired a recruiter because they do not even have an infastructure yet.
    Obviously, you are an idiot and should not apply.
     
  6. Anonymous

    Anonymous Guest

    Tonight Swiss life science company Basilea Pharmaceuticals Inc. has chosen Brickstone Square in Andover for its U.S. headquarters. Basilea will create at least 12 sales, marketing and finance-related jobs in Andover over the coming year. Basilea chose the Massachusetts site over a competing location in New Jersey. The division's president. Said: “Andover represents an ideal location for the company's U.S. headquarters because of its proximity to major highways and airports, neighbors such as Wyeth's biopharmaceutical division and a short drive to the biotechnology cluster centered in Boston and Cambridge. There is ease of recruiting as well as a convenient location.” Basilea will be the twelfth life science company in Andover, and the fortieth in the Merrimack Valley’s life science cluster. Read the Boston Business Journal story by Mark Hollmer:
     
  7. Anonymous

    Anonymous Guest

    FROM THE UK - December 8, 2006

    Basilea set to build its own sales force - 08/12/2006

    Antibiotic from Basilea effective against ‘superbug’

    Switzerland’s Basilea Pharmaceutica will step out of the lab and hit the
    commercial route to co-promote its lead product with US giant Johnson &
    Johnson.

    The Basel-based group has exercised an option to co-promote ceftobiprole,
    its cephalosporin antibiotic against the superbug methicillin-resistant Staphylococcus aureus (MRSA) with J&J affiliate Cilag in North America and major European countries. The treatment has received fast-track status from the US Food and Drug Administration, and results from a second Phase III study in skin infections are expected in the first half of 2007.

    In preparation for a launch, Basilea is looking to set up its own sales force, which it will employ to promote two other late-stage products. First up is alitretinoin, a synthetic retinoid drug for patients with severe dermatitis of the hand who do not respond to topical corticosteroid treatment; a first regulatory filing is expected next year followed by a potential launch in 2008.

    The new field force could also be used to promote another fast-track product, the antifungal isavuconazole, which could be used in conjunction with ceftobiprole and will enter Phase III this month.

    Nicholas Benedict, head of commercial strategy and operations at Basilea,
    said: “We intend to build a dynamic, effective sales and marketing
    organisation,” and the most suitable structure for that is currently being
    evaluated.

    Basilea’s decision to sell its own products went down well with analysts,
    and Morgan Stanley said: “we view it as a positive move for the
    company.”
     
  8. Anonymous

    Anonymous Guest

    FROM THE UK - MARCH 3, 2007

    Basilea share offering will help finance new sales force - 12/03/2007

    Swiss firm Basilea, which has three drugs in late-stage trials, has unveiled a share offering that could help the firm raise over $240 million.

    No stock is being offered publicly outside of Switzerland, but a Basilea spokesperson confirmed to PharmaTimes World News that the firm will offer up to 1.15 million new shares at one new share for each five held, which would be worth around 297 million Swiss francs (or some $244 million), based on the company’s closing price on March 8. There is an option to increase the offering to 1.495 million new shares and the rights cannot be traded and will lapse if not exercised. Morgan Stanley, Credit Suisse and UBS are joint global coordinators and bookrunners.

    Basilea intends to use the proceeds from the offering to set up its own sales and marketing force to commercialise its Phase III compounds, led by ceftobiprole, its cephalosporin antibiotic against the superbug methicillin-resistant Staphylococcus aureus (MRSA), which could be launched in the USA this year. Johnson & Johnson affiliate Cilag is a co-promotion partner for the drug.

    The funds will also be used to promote alitretinoin, a synthetic retinoid drug for patients with severe dermatitis of the hand who do not respond to topical corticosteroid treatment which was the subject of positive Phase III data at the beginning of the month. The money raised in the offering will also fund late-stage trials of Basilea's broad-spectrum antifungal treatment isavuconazole.

    This commitment to setting up its own specialised field force with the significant sums being raised has led the market to believe that Basilea is unlikely to be open to a takeover, rumours of which had recently pushed the stock up.
     
  9. Anonymous

    Anonymous Guest

    Basilea and Janssen-Cilag file anti-MRSA drug in Europe - 18/06/2007

    J&J backs promising pharma pipeline to drive future growth


    Basilea share offering will help finance new sales force


    Basilea stock hits record high on ceftobiprole data


    Antibiotic from Basilea effective against ‘superbug’


    Other sources:
    www.basilea.com
    www.janssen-cilag.com


    Switzerland’s Basilea says that its licensing partner Janssen-Cilag International has filed for approval of its new antibiotic ceftobiprole in Europe.

    Janssen, a Johnson & Johnson unit, has submitted a marketing authorisation application to the European Medicines Agency for ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

    Ceftobiprole is the first broad-spectrum cephalosporin to show efficacy in a large clinical trial against methicillin-resistant Staphylococcus aureus (MRSA) and demonstrated clinical activity against Gram-positive as well as Gram-negative pathogens. In clinical trials, ceftobiprole demonstrated high cure rates in patients with complicated skin infections and the firms noted that a New Drug Application for the antibiotic has already been submitted in the USA.

    The potential of the drug is considerable, and the firms noted that data from the European Antimicrobial Resistance Surveillance System shows that the prevalence of MRSA, “while varying considerably among countries,” has been rising across Europe for the past six years.

    As part of their collaboration, Basilea will co-promote the product with Janssen in the major European markets and the Swiss biotechnology firm recently raised around $240 million in a share offering, some of the proceeds of which will be used to set up its own sales and marketing force.
     
  10. Anonymous

    Anonymous Guest

    How could they be hiring a sales force?

    They have no infrastructure, no US web site, no management in place.
     
  11. Anonymous

    Anonymous Guest

    Infrastructure can be built very quickly. they just hired a sales ops guy from Sepracor. that means alignments and targeting will happen next.
     
  12. Anonymous

    Anonymous Guest

    What is his name? I heard a lot of people are bailing from Sepracor.
     
  13. Anonymous

    Anonymous Guest

    Who is the National Sales Manager?
     
  14. Anonymous

    Anonymous Guest

    Fred Graff former VP of Sales and Jack Britts former VP Marketing and Comm'l Ops

    Do you know which one will be heading the sales div? When will they begin hiring?
     
  15. Anonymous

    Anonymous Guest

    Fred Graff from Sepracor?????
     
  16. Anonymous

    Anonymous Guest

    wrong and wronger
     
  17. Anonymous

    Anonymous Guest

    Ken Farah of Dendreon fame. You're welcome.
     
  18. Anonymous

    Anonymous Guest

    THANKS.

    Basilea Pharmaceuticals, Inc. Appoints National Sales Director

    NewswireToday - /newswire/ - Hingham, MA, United States, 10/09/2007 - Phillips DiPisa completes a search assignment for Basilea Pharmaceuticals, Inc. Company appoints Ken Farah as National Sales Director for its Ceftobiprole drug.


    Phillips DiPisa, a retained executive search firm serving healthcare providers, managed care organizations, and life sciences firms, today announced that it has completed an executive search assignment for Basilea Pharmaceuticals, Inc.

    Basilea Pharmaceuticals, Inc., a newly launched U.S. subsidiary of Switzerland's Basilea Pharmaceutica, hired Ken Farah as the National Sales Director. Phillips DiPisa led the search on behalf of Basilea Pharmaceuticals.

    At Basilea, Farah will lead the company’s first sales team for Ceftobiprole, which is awaiting FDA approval to treat methicillin-resistant staff infections.

    Farah has over 25 years of sales and sales management experience launching specialty anti-infective and oncology products in the hospital markets. Most recently, Farah was a Sales Director for Dendreon Corporation. Prior, he managed regions around the country for Ortho McNeil/Alza, where he helped build the specialty sales force for the ADHD drug Concerta.

    Farah also served at ALZA, Sequus and Immunex, in capacities such as Regional Manager, Director of Strategic Oncology accounts and Oncology Account Executive. He began his career in sales at Lederle, where he rose to management in the hospital division and concentrated on antibiotic sales in the hospital marketplace.

    Basilea Pharmaceutica Ltd. is a biopharmaceutical company focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea’s products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio, including three investigational phase III drugs of which two have shown positive pivotal phase III results.

    Kevin Carroll was Phillips DiPisa’s associate responsible for this engagement.
     
  19. Anonymous

    Anonymous Guest

    Is he any good?
     
  20. Anonymous

    Anonymous Guest


    ---Anyone hear any news? Have they started the interview process with anyone yet?